Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Iridex gets Beck as new chief ; Boutacoff moved to CTO role

This article was originally published in Clinica

  • News

Executive Summary

Laser devices specialist Iridex has appointed Dominik Beck, the former US chief of eye diagnostic equipment manufacturer Haag-Streit, president and CEO. Dr Beck replaces Theodore Boutacoff, who was the co-founder of Iridex and had been leading the Mountain View, California firm since its inception in 1989 to 2005, and then from 2007 to present to help turn the company around. Mr Boutacoff will remain in the company, though this time overseeing the R&D side of the business in his new role as chief technology officer. He will also leave the board of directors and be replaced by Dr Beck. Prior to joining Haag-Streit US in 2003, Dr Beck was CEO of Zurich based Ophthalmic Development Company.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

UK MHRA Updates Assistive Tech And Borderline Regulations

See All
UsernamePublicRestriction

Register

MT097992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By